• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    NKGen Biotech, Inc. - Common Stock (NQ: NKGN )

    0.2525 -0.0029 (-1.14%)
    Streaming Delayed Price Updated: 10:58 AM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about NKGen Biotech, Inc. - Common Stock

    NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
    From NKGen Biotech
    Via GlobeNewswire
    NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)
    From NKGen Biotech
    Via GlobeNewswire
    NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
    From NKGen Biotech
    Via GlobeNewswire
    NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
    From NKGen Biotech
    Via GlobeNewswire
    NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    From NKGen Biotech
    Via GlobeNewswire
    NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report
    From NKGen Biotech, Inc.
    Via GlobeNewswire
    NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference
    From NKGen Biotech
    Via GlobeNewswire
    NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference
    From NKGen Biotech
    Via GlobeNewswire
    NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
    From NKGen Biotech
    Via GlobeNewswire
    NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
    From NKGen Biotech
    Via GlobeNewswire
    Spotlighting Unexplored Stocks in Focus: NKGN, INBS, BTBT, PRSO, MGOL
    Via AB Newswire
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies
    Via Get News
    Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies
    New York, Feb 7, 2024 - (Plato Data) - On Thursday February 2, 2024, the bio industry welcomed the parliament’s passage of a bill that adds regenerative medicine organizations to the list of those... 
    Via TheNewswire.com
    NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial
    Via Get News
    NKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial
    SANTA ANA, Calif., Dec. 29, 2023 - (Plato / Amplifi via 500NewsWire) -- NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient... 
    Via TheNewswire.com
    NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.
    Via Get News
    Exposures Product Safety
    NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.
    SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics,... 
    Via TheNewswire.com
    Exposures Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.